▲
STOCKUPSIDE.IO
Analyst Price Target Intelligence
← Full Rankings
← Back to rankings
Ranked #2082 by analyst upside · 2026-09-29
PACS
PACS Group, Inc.
Healthcare · Market Cap $7B · P/E 25.2x
ANALYST PRICE TARGET
+37.0%
implied upside to consensus target
Current Price $43.06
Consensus Target $59.0
Bull Target $62.0
Bear Target $57.0
Analysts Covering 6
ANALYST CONSENSUS - BUY
Strong Buy
2
Buy
4
Hold
0
Sell
0
52-Week Low $10.31
52-Week High $49.49
YTD Return +9.0%
FUNDAMENTALS
Market Cap $7B
P/E Ratio (TTM) 25.2x
Forward P/E 15.9x
EPS (TTM) $1.71
PEG Ratio 1.04
Dividend Yield N/A
Revenue (TTM) $5.6B
Profit Margin 4.8%
52-WEEK RANGE
52-Week Low $10.31
52-Week High $49.49
Current Price $43.06
Bear Target $57.0
Bull Target $62.0
● Now $43.06 ● Target $59.0
TRADING DATA
Avg Volume 829K
YTD Return +9.0%
Analyst Count 6
Consensus Buy
Upside to Target +37.0%
Last Updated 2026-09-29

ANALYST SUMMARY

PACS Group, Inc. (PACS) is currently trading at $43.06 with a Wall Street consensus price target of $59.0, implying potential upside of 37.0% over the next 12 months. 6 analysts currently cover PACS, with a consensus rating of Buy - 100% of analysts rate the stock a Buy or Strong Buy. The most bullish analyst has a price target of $62.0, while the most cautious has a target of $57.0.

PACS operates in the Healthcare sector with a market capitalisation of $7B. The stock is up 9.0% year-to-date and is currently trading near the upper end of its 52-week range of $10.31 – $49.49.

SIMILAR STOCKS

Other Healthcare stocks with comparable size and valuation.

RECENT ANALYST CALLS

Upgrade/downgrade history for PACS, with each firm's 90-day track record across all stocks we track. See full firm rankings →

JP Morgan - Reiterated
Overweight → Overweight 2026-09-04 43% win rate (7 calls)
Oppenheimer - Reiterated
Outperform → Outperform 2026-08-10 14% win rate (7 calls)
UBS - Reiterated
Buy → Buy 2026-08-06 33% win rate (6 calls)
RBC Capital - Reiterated
Outperform → Outperform 2026-08-06 Building track record
Truist Securities - Reiterated
Buy → Buy 2026-08-06 Building track record
UBS - Reiterated
Buy → Buy 2026-07-08 33% win rate (6 calls)
Truist Securities - Reiterated
Buy → Buy 2026-05-18 Building track record
Oppenheimer - Reiterated
Outperform → Outperform 2026-05-13 14% win rate (7 calls)
HISTORICAL SNAPSHOT

Point-in-time data from StockUpside's daily snapshots. Tracks price, analyst target, upside %, consensus, and analyst count.

Loading…
ANALYST CONVICTION SCORE
70
out of 100
Coverage depth
15/30
Consensus clarity
28/30
Vote unanimity
25/25
Rating stability
2/15

Measures analyst agreement, not fundamental quality. A high score means analysts broadly agree on this call - not that the stock will go up.

See 4,000+ stocks ranked by analyst upside

StockUpside.io tracks analyst consensus price targets across thousands of US-listed stocks, updated every day. The full ranked list is available with a Pro subscription.

View Full Rankings →